ArticleMolecular medicine reports2019
In vitro analysis of the role of tumor necrosis factor‑stimulated gene‑6 in keloid.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Advances in the pathogenesis and clinical application prospects of tumor biomolecules in keloid.Burns & trauma · 2022Review
- Recombinant TSG-6 protein inhibits the growth of capsule fibroblasts in frozen shoulder via suppressing the TGF-β/Smad2 signal pathway.Journal of orthopaedic surgery and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing number of studies have demonstrated that tumor necrosis factor‑stimulated gene‑6 (TSG‑6) has a key role in the progression of fibrosis; however, the exact effects of TSG‑6 in keloid fibroblasts (KFs) remain unknown. The aim of the current study was to investigate the role of TSG‑6 in the pathogenesis of keloids. Primary fibroblasts from 10 patients with keloid were cultured and transfected with pLVX‑Puro or pLVX‑Puro‑TSG‑6. Alterations of TSG‑6 expression were then determined by reverse transcription‑polymerase chain reaction (RT‑PCR) and regulation was observed in KFs transfected with pLVX‑Puro‑TSG‑6. Compared with the control group, transfection with pLVX‑Puro‑TSG‑6 induced growth suppression, cell apoptosis and G2/M arrest in KFs. In addition, the mitochondrial apoptosis pathway was activated in KFs transfected with pLVX‑Puro‑TSG‑6. These findings indicate that TSG‑6 is a novel regulator of keloid fibrogenesis, and thus could be used/targeted TSG‑6 as a promising treatment for keloid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.